Releases
IBRX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest ImmunityBio Inc (IBRX) stock and general news. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.